

# SINGBAO INTERNATIONAL CO. LTD

INVESTOR CONFERENCE –DECEMBER 24 , 2021

SINGBAO GROUP PROFILE AND THIRD QUARTER 2020

OPERATING OVERVIEW AND FUTURE PROSPECTS

GENERAL MANAGER     K. J. HUANG

# DISCLAIMER

- The figures of briefing consolidated financial statements are compiled in accordance with the guidelines of the International Financial Reporting Standards (IFRSs) approved by the securities issuer's financial statements and prepared in accordance with the International accounting standards, interpretation and interpretation bulletins, and the verification by certified accountants.
- The Company has not issued any financial forecast. The financial statements, the business descriptions and the Company 's future business prospects in this Briefing may differ from those of actual operations in the future. Such differences may include changes in market demand, price fluctuations, International economic conditions and fluctuations of exchange rate, and other risks that the Company cannot grasp.
- The information gathered in this Briefing is from various sources within and outside the Company. If there is any change in the future, please refer to the information announced by the Public Information Observatory.

# 一、Company Profile

Stock Code : 6130

Company Name : Singbao International Co.Ltd.

President & GM : Mr. KJ Huang

Contributed Capital : NTD\$375,000,000

BUSINESS SCOPE : Western Medicines、ANTIGEN SELF-TEST  
SALES

、Solar energy generation。

## 二. Business review

### **Our business including:**

A. Trading of generic drug.

B. COVID-19 Antigen Self.Test


C. Group Physiologicall Nformation Monitor Lora GPS Electrocardiogram

Temperature+lora GPS Electrocardiogram Temperature

D. Solar power generation.

E. Real estate sales and leasing.

# 三.Product sales category





AI big data  
preventive  
medicine report

Medical care  
connection

Long-distance  
silver hair care

Critical  
judgment

LoRa+Bluetooth  
5.0

**Group Physiologically Information  
Monitor LoRa GPS  
Electrocardiogram  
Temperature+LoRa GPS  
Electrocardiogram Temperature**

Real-time  
monitoring

GPS satellite  
positioning

Physiological  
measurement

Easy to wear

**ALERT  
SARS-  
CoV-2  
Antigen  
Self-Test**



**COVID-  
19  
Antigen  
Self-Test**



**FORA /  
VTRUST  
COVID-19  
Antigen  
Self-Test**




# 四、Financial Analysis

Unit : NT\$ thousand	September 30,2021		September 30,2020		December 31,2020	
	Amount	%	Amount	%	Amount	%
Total Assets	543,641	100	1,079,212	100	1,221,465	100
Current Assets	67,088	12	97,643	9	125,134	10
Cash and Cash Equivalents	28,116	5	56,099	5	88,938	7
Receivables - net Abstract	10,695	2	11,271	1	9,157	1
Other Receivable	3,971	-	5,445	-	1,815	-
Inventories	5,195	1	5,449	1	4,965	1
Prepayments	4,516	1	7,788	1	4,361	-
Other current financial assets	14,584	3	11,562	1	15,881	1
Non-Current Assets	476,553	88	981,569	91	1,096,331	90
Equity investments under equity method, net	102,385	19	21,870	2	18,195	2
Property, Plant and Equipment	80,785	15	85,858	8	84,589	7
Right-of-use asset	13,564	3	21,888	2	20,461	2
Investment Property	221,612	41	777,103	72	806,220	66
Intangible asset	12,870	2	16,307	2	15,447	1
Total Liabilities	242,716	45	666,427	61	788,887	64
Current liabilities	73,523	14	357,856	32	407,361	33
non-current liabilities	169,193	31	308,571	29	381,526	31
Total Equity	300,925	55	412,785	39	432,578	36



# Financial Analysis




	September 30 ,2021	September 30,2020	December 31 ,2020
Current assets	67,088	97,643	125,134
Cash and Cash Equivalentts	28,116	56,099	88,938
Reveivables-net Abstract	10,695	11,271	9,157
Non-Current Assets	476,553	981,569	1,096,331
Total Assets	543,641	1,079,212	1,221,465
Current Liabilities	73,523	357,856	407,361
Other Non-Liabilities	169,193	308,571	381,526
Total Liabilities	242,716	666,427	788,887
Total Equity	300,925	412,785	432,578

# Financial performance

Unit : NT\$ thousand

ITEM/YEAR	September 30,2021	September 30,2020	Increase(decrease) Amount	Ratio of Change %
Net sales revenue	80,677	100,780	(20,103)	-19.95
Gross profit from operations	40,920	73,753	(32,833)	-44.52
Gross margin	51%	73%	(22)	-30.14
Total operating expenses	50,966	87,294	(36,328)	-41.62
Operating expense Ratio	63%	86%	(23)	-26.74
Operating Profit(loss)	7,775	(7,669)	15,444	-201.38
Operating Profit Ratio	10%	-7%	17	-242.86
Non-operating income and expenditure	12,825	-1,264	14,089	-1,114.64
Net profit after tax	20,600	-8,933	29,533	-330.61
EPS(NTD)	0.67	-0.60		


# Financial performance



	January-September 2021	January-September 2020	January-December 2020
Operating revenue	80,677	100,780	137,870
Operating Margin	40,920	73,753	98,711
Operating Expense	50,966	87,294	117,328
Operating Profit(loss)	7,775	-7,669	-8,355
Non-operating income and expenditure	12,825	-1,264	-8,579
Net profit after tax	20,600	-8,933	-16,934

Unit : NT\$ thousand

# Consolidated revenue proportion



# 五、Future Prospect

- Continue to develop high-end generic drugs, actively deploy marketing channels, cultivate excellent agents and distributors, and expand market share and market influence in medical retail channels, so as to lay the foundation for the company's sustainable development and long-term profitability.
- In the second half of this year, we will start to sell GPIM group physiological information monitoring system + L-GET full-function physiological monitoring watch, and develop towards medical care
- Continue to develop places suitable for solar power generation, and develop toward energy storage systems. Combining energy creation, energy storage, energy saving, and smart system integration will become the four main axes of Taiwan's future development of renewable energy ·
- Continuously improve operating efficiency, increase profitability, strengthen financial structure, reduce operating costs, increase net cash flow, and facilitate company development and increase competitiveness ·

THANK YOU FOR YOUR LISTENING